Microscopic Polyangiitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for microscopic polyangiitis. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
4
Active US patents
35/100
Avg vulnerability
$400M
Annual revenue covered

Originators in Microscopic Polyangiitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Chemocentryx 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating microscopic polyangiitis. Each bar = one year. Y-axis scaled to peak year (2 patents).

1
31
1
34
2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tavneos
AVACOPAN
 Chemocentryx 4 35 $400M 2031-02-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11603356 Tavneos method of use 70 2039-11-27
11951214 Tavneos formulation 55 2039-11-27
8445515 Tavneos composition of matter 10 2031-02-03
8906938 Tavneos composition of matter 4 2034-01-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8906938 Tavneos composition of matter 4 2034-01-06
8445515 Tavneos composition of matter 10 2031-02-03
11951214 Tavneos formulation 55 2039-11-27
11603356 Tavneos method of use 70 2039-11-27

Related